Drug Type Small molecule drug |
Synonyms Arginine/Lysine, L-Arginine Hydrochloride / L-Lysine Hydrochloride, L-Lysine HCl/L-Arginine HCl + [5] |
Target- |
Mechanism- |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date EU (25 Jul 2019), |
RegulationOrphan Drug (KR) |
Molecular FormulaC6H15ClN2O2 |
InChIKeyBVHLGVCQOALMSV-JEDNCBNOSA-N |
CAS Registry657-27-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Radiation Injuries | EU | 25 Jul 2019 | |
Radiation Injuries | IS | 25 Jul 2019 | |
Radiation Injuries | LI | 25 Jul 2019 | |
Radiation Injuries | NO | 25 Jul 2019 |
Phase 2 | 48 | Standard of care ADT + (HMB + arginine + glutamine) (Standard of Care ADT + (HMB + AG)) | dpsujjnrwo(rulilrmdov) = toysgyxeyb mqflyaazpa (btmfxkrjga, mhcacqunxy - pdxbbpujdz) View more | - | 22 Sep 2023 | ||
Standard of care ADT (Standard of Care ADT) | dpsujjnrwo(rulilrmdov) = tlwekwllpq mqflyaazpa (btmfxkrjga, vzehdwmdmf - njlwvpkryg) View more | ||||||
Phase 2 | 22 | amcktmrduy(xzxrxwgqkv) = avduehgcyd ztvfbqmhki (hrsrozqfpg ) | - | 20 May 2008 |